SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (8490)12/27/2000 4:15:42 PM
From: Vector1  Read Replies (1) | Respond to of 9719
 
JD, I took it from the press release,


NEW YORK, Oct 16 (Reuters) - Biotechnology company Corixa
Corp. <CRXA.O> said Monday it agreed to buy Coulter
Pharmaceutical Inc. <CLTR.O>, a maker of prospective cancer
treatment Bexxar, for more than $900 million in stock.
The purchase price is based on a fixed exchange ratio of
1.003 shares of Corixa common stock for each share of South San
Francisco-based Coulter common stock outstanding at the time of
closing. Corixa shares closed at $44-3/16 on Friday, while
Coulter closed at $30-15/16.



To: jayhawk969 who wrote (8490)12/27/2000 4:33:28 PM
From: lwd  Respond to of 9719
 
J.D.,
Schwab confirmed for me that it was 1.003.
Lisa


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News